April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Visual Outcomes of Myopic Choroidal Neovascularization Related to Dome Shaped Macula After Antiangiogenic Therapy
Author Affiliations & Notes
  • Cristina Marin Lambies
    La Fe Hospital, Valencia, Spain
  • Rosa Dolz-Marco
    La Fe Hospital, Valencia, Spain
  • Sebastián Martínez-Castillo
    La Fe Hospital, Valencia, Spain
  • Carlos Mateo
    Instituto de Microcirugía Ocular, Barcelona, Spain
  • David Salom
    La Fe Hospital, Valencia, Spain
  • Roberto Gallego-Pinazo
    La Fe Hospital, Valencia, Spain
  • J. Fernando Arévalo
    Clínica Oftalmológica Centro Caracas, Caracas, Venezuela
  • Manuel Díaz-Llopis
    La Fe Hospital, Valencia, Spain
  • Footnotes
    Commercial Relationships  Cristina Marin Lambies, None; Rosa Dolz-Marco, None; Sebastián Martínez-Castillo, None; Carlos Mateo, None; David Salom, None; Roberto Gallego-Pinazo, None; J. Fernando Arévalo, None; Manuel Díaz-Llopis, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2715. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cristina Marin Lambies, Rosa Dolz-Marco, Sebastián Martínez-Castillo, Carlos Mateo, David Salom, Roberto Gallego-Pinazo, J. Fernando Arévalo, Manuel Díaz-Llopis; Visual Outcomes of Myopic Choroidal Neovascularization Related to Dome Shaped Macula After Antiangiogenic Therapy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2715.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Dome-shaped macula is a recently described new type of myopic posterior staphyloma. It may be associated with atrophic changes in the retinal pigment epithelium and less frequently with myopic choroidal neovascularization (CNV). The purpose of this study was to evaluate the efficacy of intravitreal ranibizumab in the treatment of myopic CNV associated with dome-shaped macula

Methods: : Retrospective, interventional case series study. Seventeen myopic eyes from 17 patients affected with dome shaped macula and subfoveal or juxtafoveal CNV were treated with three monthly intravitreal injections of 0,5 mg ranibizumab followed by a treatment as needed. Best corrected visual acuity (BCVA), fundus biomicroscopy, fluorescein angiography and optical coherence tomography (OCT) were performed at baseline and at the final examination. Changes in BCVA and OCT central retinal thickness were the main outcome measures.

Results: : Mean age was 54,5 +/- 12,9 years and mean refractive error -9,3 +/- 3,9 D. Eight eyes (47%) had bilateral dome-shaped macula. The mean number of ranibizumab injections during a mean follow-up of 19,3 months (range 11 - 30) was 4,7 +/- 1,7 (range 2-7). The mean baseline logarithm of the minimum angle resolution (logMAR ) BCVA was 0,55 +/- 0,80 and improved to 0,29 +/- 0,49 at final examination (p < 0,001). The mean central retinal thickness was 383,5 +/- 122,7 at baseline and 277 +/- 57,2 at the final examination (p<0.001).

Conclusions: : Intravitreal ranibizumab may be an effective treatment for myopic CNV related to dome shaped macula, resulting in functional and anatomic improvements. Further randomized studies are warranted.

Keywords: choroid: neovascularization • myopia • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.